Elevated BLOS is very common (2/3 of Adult Americans) and causes elevated levels of ROS, which may be oxidizing the experimental drug into an inactive form or a lethal form.  Why not manage BLOS in Phase 2 patients for a better evaluation of the experimental drug?

Medical researchers may want to go back and check the health state of the patients in a failed Phase 2 clinical trial.